NewAmsterdam Pharma Company N.V. Warrant (NAMSW)

• Market cap: $64.3M
• 1 day: 0.43%
• 5 days: 2.19%
• 1 month: 31.14%
• 3 months: 45.93%
• 6 months: 13.11%
• Year to date: -2.85%
• 1 year: 100.57%
• 5 years: 1,488.64%
• 10 years: 1,488.64%
• Sector: Healthcare
• Industry: Biotechnology

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

27.13% more ownership

Funds ownership: 1.21% [Q1] → 28.34% (+27.13%) [Q2]

0% more funds holding

Funds holding: 10 [Q1] → 10 (+0) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

15% less capital invested

Capital invested by funds: $12.3M [Q1] → $10.4M (-$1.89M) [Q2]